GenSight Biologics reports September cash position

GenSight Biologics said cash and cash equivalents were EUR0.7 million at Sept. 30, 2026, versus EUR1.7 million at June 30. It also said net funding needs are estimated at about EUR16 million and that a going-concern material uncertainty remains.